Intersect ENT Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
433
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.2B
Intersect ENT General Information
Description
Developer of integrated medical technologies designed to improve care for those suffering from chronic rhinosinusitis. The company offers mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses, enabling patients to experience better health outcomes and enhanced quality of life.
Contact Information
Website
www.intersectent.comCorporate Office
- 1555 Adams Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1555 Adams Drive
- Menlo Park, CA 94025
- United States
Intersect ENT Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 13-May-2022 | $1.2B | Completed | Generating Revenue | ||
| 15. Merger/Acquisition | 08-Jul-2020 | Cancelled | Generating Revenue | |||
| 14. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 13. Secondary Transaction - Open Market | 31-Jan-2018 | Completed | Generating Revenue | |||
| 12. PIPE | 31-Aug-2016 | Completed | Generating Revenue | |||
| 11. 2PO | 03-Jun-2016 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 31-Jan-2016 | Completed | Generating Revenue | |||
| 9. PIPE | 05-Nov-2015 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 31-Mar-2015 | $146M | Completed | Generating Revenue | ||
| 7. IPO | 24-Jul-2014 | $55M | $146M | Completed | Generating Revenue |
Intersect ENT Comparisons
Industry
Financing
Details
Intersect ENT Competitors (11)
One of Intersect ENT’s 11 competitors is Spine Wave, a Venture Capital-Backed company based in Shelton, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spine Wave | Venture Capital-Backed | Shelton, CT | ||||
| NEUROMARK | Venture Capital-Backed | Braintree, MA | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| CardioFocus | Venture Capital-Backed | Marlborough, MA |
Intersect ENT Patents
Intersect ENT Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250295507-A1 | Catheter for delivering a nasal stent | Pending | 22-Mar-2024 | ||
| WO-2025199445-A1 | Sinus and nasal stent | Pending | 22-Mar-2024 | ||
| AU-2020336462-A1 | Submucosal bioresorbable drug eluting platform | Inactive | 30-Aug-2019 | ||
| CA-3152762-A1 | Submucosal bioresorbable drug eluting platform | Pending | 30-Aug-2019 | ||
| EP-4021343-A1 | Submucosal bioresorbable drug eluting platform | Pending | 30-Aug-2019 | A61M37/0069 |
Intersect ENT Signals
Intersect ENT Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Cheyenne Partners | Venture Capital | Minority | ||
| Duff Ackerman & Goodrich | PE/Buyout | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| Harmony Partners | Venture Capital | Minority |
Intersect ENT Acquisitions (1)
Intersect ENT’s most recent deal was a Merger/Acquisition with Fiagon for . The deal was made on 02-Oct-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Fiagon | 02-Oct-2020 | Merger/Acquisition | Surgical Devices |
Intersect ENT ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
15.53 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Intersect ENT FAQs
-
When was Intersect ENT founded?
Intersect ENT was founded in 2003.
-
Where is Intersect ENT headquartered?
Intersect ENT is headquartered in Menlo Park, CA.
-
What is the size of Intersect ENT?
Intersect ENT has 433 total employees.
-
What industry is Intersect ENT in?
Intersect ENT’s primary industry is Therapeutic Devices.
-
Is Intersect ENT a private or public company?
Intersect ENT is a Private company.
-
What is the current valuation of Intersect ENT?
The current valuation of Intersect ENT is .
-
What is Intersect ENT’s current revenue?
The current revenue for Intersect ENT is .
-
How much funding has Intersect ENT raised over time?
Intersect ENT has raised $151M.
-
Who are Intersect ENT’s investors?
Aisling Capital, Cheyenne Partners, Duff Ackerman & Goodrich, Foresite Capital, and Harmony Partners are 5 of 12 investors who have invested in Intersect ENT.
-
Who are Intersect ENT’s competitors?
Spine Wave, NEUROMARK, Biotronik, Boston Scientific, and CardioFocus are some of the 11 competitors of Intersect ENT.
-
When was Intersect ENT acquired?
Intersect ENT was acquired on 13-May-2022.
-
Who acquired Intersect ENT?
Intersect ENT was acquired by Medtronic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process